Macitentan in the Young—Mid-term Outcomes of Patients with Pulmonary Hypertensive Vascular Disease treated in a Pediatric Tertiary Care Center

• Published in: Paediatric drugs Vol. 25; no. 4; pp. 467 - 481
• Main Authors: Albinni, Sulaima, Heno, Julian, Pavo, Imre, Kitzmueller, Erwin, Marx, Manfred, Michel-Behnke, Ina
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.07.2023; Springer; Springer Nature B.V
• Subjects: Adolescent; Adult; Adults; Algorithms; Blood pressure; Care and treatment; Child; Child, Preschool; Children; Congenital diseases; Disease; Diseases; Drug dosages; Heart failure; Hemodynamics; Humans; Hypertension, Pulmonary - drug therapy; Internal Medicine; Medicine; Medicine & Public Health; Natriuretic Peptide, Brain - blood; Original; Original Research Article; Patient outcomes; Pediatrics; Peptides; Pharmacotherapy; Prospective Studies; Pulmonary arteries; Pulmonary hypertension; Sulfonamides - adverse effects; Sulfonamides - therapeutic use; Tertiary Care Centers; Austria
• ISSN: 1174-5878; 1179-2019
• DOI: 10.1007/s40272-023-00573-y

Background Pulmonary hypertension (PH) is a severe hemodynamic condition with high morbidity and mortality. Approved targeted therapies are limited for pediatric subjects, and treatments are widely adopted from adult algorithms. Macitentan is a safe and effective drug used for adult PH, but data on pediatric patients are limited. In this prospective single-center study, we investigated mid- and long-term effects of macitentan in children with advanced pulmonary hypertensive vascular disease. Methods Twenty-four patients were enrolled in the study for treatment with macitentan. Efficacy was determined by echo parameters and brain natriuretic peptide levels (BNP) at 3 months and 1 year. For detailed analysis, the entire cohort was subgrouped into patients with congenital heart disease-related PH (CHD-PH) and non-CHD-PH patients, respectively. Results Mean age of the patients was 10.7 ± 7.6 years; median observation period was 36 months. Twenty of 24 patients were on additional sildenafil and/or prostacyclins. Two of 24 patients discontinued because of peripheral edema. Within the entire cohort, BNP levels and all echo measures such as right ventricular systolic pressure (RVSP), right ventricular end-diastolic diameter (RVED), tricuspid annular plane systolic excursion (TAPSE), pulmonary velocity time integral (VTI), and pulmonary artery acceleration time (PAAT) improved significantly after 3 months ( p ≤ 0.01), whereas in the long term significant improvement persisted for BNP levels (−16%), VTI (+14%) and PAAT (+11%) ( p  < 0.05). By subgroup analysis, non-CHD PH patients showed significant improvements in BNP levels (−57%) and all echo measures (TAPSE +21%, VTI +13%, PAAT +37%, RVSP −24%, RVED −12%) at 3 months ( p  ≤ 0.01), whereas at 12 months, improvements persisted ( p  < 0.05) except for RVSP and RVED (nonsignificant). In CHD-PH patients, none of the measures changed (nonsignificant). 6-MWD (distance walked in 6 minutes) slightly increased but was not statistically evaluated. Conclusion Data presented herein account for the largest cohort of severely affected pediatric patients receiving macitentan. Overall, macitentan was safe and associated with significant beneficial effects and sustained positive signals after 1 year, albeit in the long term disease progression remains a major concern. Our data suggest limited efficacy in CHD-related PH, whereas favorable outcomes were mainly driven by improvements in patients with PH not related to CHD. Larger studies are needed to verify these preliminary results and to prove efficacy of this drug in different pediatric PH entities.